| Objective: To observe and discuss the application of children withcough variant asthma montelukast with inhaled corticosteroids therapy ofclinical effect and value，in order to provides an evidence for the betterantibacterial drugs specification.Methods: All patients during February2013to August2013, intotal of100who are diagnosed as cough variant asthma in our hospital areinvolved in this retrospective study. All outpatients are divided in thesequence that an odd number into the A group, enter the group ofeven-numbered B；A Group: Montelukast combined inhaled corticosteroidtherapy, group B: single treatment with inhaled corticosteroids. Wereobserved in children with clinical efficiency, lung function changes，adverse reactions．Followed up for six months，observed within a month,within three months，relapse within six months of cough symptoms.Results:(1) A group of the children after treatment get the score of cough：(1.1±0.5), the score of group B：(3.2±0.8), the difference is statistically significant.(2)the PEF of A group of children after treatment (t=8.7691, p=0.03), FEV1(t=7.2159, p=0.02), FEV1/FVC (t=8.3624, p=0.02) its values were significantly higher than that of group B.(3) A group of children in the proportion of the acuteattacks of cough was8.00%(4/50), group B was26.00%(13/50), the recurrence rate of group A was lower than that in group B (χ2=9.2147, p=0.01<0.05), the difference between them is statistically significant.(4) A group of children during treatment the incidence ofadverse reactions was4.00%(2/50), group B was6.00%(3/50), there’s no obvious difference (χ2=3.5479, p=0.28).Conclusion: Montelukast combined with inhaled corticosteroidtherapy for children with cough variant asthma than single hormonetherapy can significantly alleviate clinical symptoms. It is confirmed safe，and also worthy of further promotion; But this article is only6monthsfollow-up period，there still needs further clinical trials of the effect toclear. |
PDF Full Text Request